Balchem vs Ingevity
Balchem and Ingevity are similar in size: $1.04bn and $1.17bn of revenue in their latest fiscal years. Balchem grew faster (8.8% against -2.7%). Balchem kept more of each dollar of sales as profit: a net margin of 14.9% against -14.3%.
| Latest fiscal year | BalchemBCPC, 2025 | IngevityNGVT, 2025 |
|---|---|---|
| Revenue | $1.04bn | $1.17bn |
| Revenue growth | 8.8% | -2.7% |
| Net income | $155m | −$167m |
| Operating margin | — | 35.9% |
| Net margin | 14.9% | -14.3% |
| Return on equity | 12.9% | -148.6% |
| Free cash flow | $217m | $274m |
| Cash | $74.6m | $78.1m |
| Total debt | $164m | $1.21bn |
| Debt to equity | — | 4079.5% |
| Dividend per share | $0.96 | — |
| Dividend yield | 0.6% | — |
| Share buybacks | $108m | $56.3m |
| Employees | — | 1,500 |
| Market value | $5.64bn | $2.55bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 72 (Strong) | 74 (Strong) |
| Insider trades, 12 months | 0 buys, 5 sales | 0 buys, 10 sales |